Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years
Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years
Zymeworks Inc. (NASDAQ:ZYME) shareholders should be happy to see the share price up 19% in the last month. But that doesn't change the fact that the returns over the last three years have been stomach churning. Indeed, the share price is down a whopping 73% in the last three years. So it's about time shareholders saw some gains. Of course the real question is whether the business can sustain a turnaround.
纳斯达克:ZYME股东应该高兴地看到上个月股票价格上涨了19%。但过去三年的回报率令人心烦意乱。事实上,股价在过去三年中暴跌了73%。因此,股东看到了一些收益,这是时候了。当然,真正的问题在于业务能否维持反转。
While the stock has risen 9.5% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.
尽管股票在过去一周上涨了9.5%,但长期股东仍处于亏损状态。让我们看看基本面能告诉我们什么。
Zymeworks wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
在过去的十二个月中,Zymeworks没有盈利,因此其股票价格与每股收益(EPS)之间不太可能存在强相关性。可以说,营业收入是我们的下一个最佳选择。当一家公司不盈利时,我们通常希望看到良好的营业收入增长。这是因为快速的营业收入增长可以轻松地推断出预测的利润,往往相当可观。
Over three years, Zymeworks grew revenue at 63% per year. That is faster than most pre-profit companies. So why has the share priced crashed 20% per year, in the same time? You'd want to take a close look at the balance sheet, as well as the losses. Ultimately, revenue growth doesn't amount to much if the business can't scale well. If the company is low on cash, it may have to raise capital soon.
在过去的三年中,Zymeworks的营业收入每年增长了63%,比大多数还未实现盈利的公司要快。那么为什么股票在同一时间暴跌了20%呢?您需要仔细查看资产负债表以及亏损情况。最终,如果业务无法很好地扩展,营业收入增长就不会对业务产生太大影响。如果公司资金不足,可能很快就不得不筹集资金。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240719/0-c57c5abc56373c469a2121186b23f619-0-b380326527ef776d25672cffb88f6bf0.png/big)
This free interactive report on Zymeworks' balance sheet strength is a great place to start, if you want to investigate the stock further.
如果您想进一步调查股票,这份有关Zymeworks资产负债表实力的免费互动报告是一个很好的起点。
A Different Perspective
不同的观点
It's good to see that Zymeworks has rewarded shareholders with a total shareholder return of 29% in the last twelve months. That certainly beats the loss of about 10% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Zymeworks (of which 1 doesn't sit too well with us!) you should know about.
很高兴看到Zymeworks在过去十二个月中以总股东回报率29%回报了股东。这当然超过了过去五年每年约10%的亏损。我们通常更注重长期绩效而非短期绩效,但最近的改善可能预示着业务内部的(积极)拐点。
But note: Zymeworks may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:Zymeworks可能不是最好的股票购买选择。因此,请查看这个免费的有过去盈利增长(并有进一步增长预测)的有趣公司列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。